Allogene Therapeutics Inc

Healthcare · Biotechnology

1.50$ -2.6% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Allogene Therapeutics Inc (ALLO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 550 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ALLO
Line item	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	–	149	299	435	774	749	734	696	718	689	1,259	1,223	1,228	1,179	1,127	1,079	1,051	965	948	888	822	747	771	712	643	586	647	589	549	508	471	440	416	396	550
Current Assets	–	144	294	247	468	477	512	510	545	504	910	854	845	716	602	503	471	470	513	569	529	481	502	473	459	395	457	304	303	292	283	261	258	273	340
Cash	–	144	294	83	721	93	650	161	175	136	280	158	183	237	224	190	173	85	96	74	62	110	155	69	83	51	171	51	75	42	52	38	52	30	39
Cash & Short-Term Investments	–	–	294	244	721	466	650	501	531	493	900	841	828	700	588	483	457	449	490	552	517	471	492	466	449	385	445	292	292	280	273	252	250	267	333
Receivables	–	–	–	–	3.1	3.4	3.3	2.3	2.4	0.2	0.8	2.3	5.2	6.3	4.3	6.2	5.8	9.0	12	5.8	3.3	2.2	1.1	1.6	1.7	1.7	2.0	2.8	1.9	2.3	1.7	2.1	1.5	1.3	–
Inventory	–	–	–	–	-262	–	-148	–	-58	–	–	–	–	-4.5	-4.3	-9.4	-20	-11	-12	-5.8	-62	-12	-1.1	-1.6	-1.7	–	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	–	3.5	3.5	4.7	8.6	53	68	77	101	110	127	103	119	123	165	126	123	120	117	114	196	110	106	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	1.1	1.1	0.9	0.8	0.6	0.5	0.3	0.2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	0.0	17	17	604	71	68	78	76	89	82	95	104	148	109	103	109	126	109	146	148	155	155	148	129	131	125	132	125	127	123	126	124	123	117	114
Current Liabilities	0.0	15	15	159	29	27	38	33	33	27	41	50	94	55	46	53	48	37	45	49	54	60	55	38	37	31	37	33	36	30	32	32	33	28	32
Short-Term Debt	–	–	–	140	–	–	–	–	1.7	–	–	51	3.0	52	–	–	3.2	–	5.3	5.8	6.0	6.2	6.4	6.6	6.8	6.9	7.2	7.4	7.5	7.6	7.8	8.0	8.2	8.4	–
Accounts Payable	–	1.3	1.3	3.1	12	13	24	8.0	9.3	7.2	9.1	10	10	15	11	11	10	8.7	9.7	11	14	15	10	6.2	5.9	5.8	13	5.5	5.4	5.1	4.9	3.7	4.3	4.9	6.0
Long-Term Debt	–	–	–	26	34	35	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	0.0	0.0	282	-168	703	681	656	620	629	607	1,163	1,119	1,080	1,070	1,024	970	925	855	802	740	667	592	623	583	512	461	515	464	422	385	345	315	293	279	436
Retained Earnings	0.0	-138	-138	-181	-212	-243	-284	-335	-396	-451	-512	-578	-646	-679	-750	-828	-895	-983	-1,058	-1,141	-1,235	-1,335	-1,413	-1,474	-1,562	-1,627	-1,694	-1,760	-1,820	-1,880	-1,930	-1,972	-2,011	-2,053	-2,096
Shares Outstanding	44	44	114	114	82	97	100	102	105	109	115	127	130	132	135	137	139	141	143	144	144	145	147	168	168	169	190	209	211	215	219	222	221	240	329

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings